The Alliance for Regenerative Medicine (ARM) is an international community of small and large companies, non-profit research institutions, patient organizations, and other sector stakeholders dedicated to realizing the promise of regenerative medicine for patients around the world.
ARM’s events bring together industry leaders, investors, policy makers, clinicians, and patients to network, partner, and learn about the latest clinical and commercial successes and challenges facing the sector.
Join ARM for the 9th Annual Cell & Gene Therapies State of the Industry Briefing, a top-level gathering for key stakeholders in the field. This event will highlight the commercialization of cell-based therapies for oncology, as well as an in-depth conversation between top CEOs and executives regarding future inflection points for gene therapies expected in 2019.
Regenerative medicine includes gene therapies, cell therapies, and tissue-engineered products intended to augment, repair, replace, or regenerate organs, tissues, cells, genes, and metabolic processes in the body.
Regenerative medicine aims to alter the current practice of medicine by treating the root causes of disease and disorders.
ARM takes the lead on the most important issues facing the regenerative medicine and advanced therapy sector today:
ARM is a global community of therapeutic companies small & large, non-profit research institutions, patient organizations, and tool and technology providers. Working with our members and policymakers, we foster investment, research & development, and the successful commercialization of safe and effective treatments and cures for patients around the world.
